FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Burton Paul		 2. Issuer Name and Ticker or Trading Symbol

Moderna, Inc. [ MRNA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

200 TECHNOLOGY SQUARE, SUITE 300		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/16/2022
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $121.08 6/16/2022  A   6902    6/16/2023 (1)6/16/2032 Common Stock 6902 $0 6902 D  
Restricted Stock Units $0 6/16/2022  A   3663     (2) (2)Common Stock 3663 $0 3663 D  
Stock Option (Right to Buy) $121.08 6/16/2022  A   19772    6/16/2024 (3)6/16/2032 Common Stock 19772 $0 19772 D  
Restricted Stock Units $0 6/16/2022  A   10990     (4) (4)Common Stock 10990 $0 10990 D  
Explanation of Responses:
(1) 25% of this option will vest and become exercisable on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
(2) 25% of the shares subject to this restricted stock unit award will vest on June 16, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
(3) 50% of this option will vest and become exercisable on June 16, 2025 and the remaining 50% will vest and become exercisable on June 16, 2026, subject to the recipient's continued service.
(4) 50% of the shares subject to this restricted stock unit award will vest on June 16, 2025 and the remaining 50% will vest on June 16, 2026, subject to the recipient's continued service.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Burton Paul
200 TECHNOLOGY SQUARE
SUITE 300
CAMBRIDGE, MA 02139

Chief Medical Officer
Signatures
/s/ Brian Sandstrom, as Attorney-in-Fact6/21/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Moderna.